Updated clinical development strategy based on positive data In the third quarter of 2025, Mendus shaped up its clinical development plans for the lead program vididencel in myeloid malignancies.The u ...
Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML Remains on track to initiate Phase 3 pivotal trial of ELVN-001 ...
TipRanks on MSN
Enliven reports Q3 EPS (32c) vs. (48c) last year
As of September 30, the company had cash, cash equivalents and marketable securities totaling $477.6M, expected to provide cash runway into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback